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Abstract
Objective: In contrast to the clinical evidence, experimental studies showed that chronic hypoxia (CH) confers a certain degree of protection
against ischaemia—reperfusion damage. We studied the effects of daily reoxygenation during CH (CHReox) on hearts exposed to ischaemia—
reperfusion. We also separated the intrinsic effects on the myocardium of CH and CHReox from those related to circulatory and nervous factors.
Methods: Fifty-one Sprague-Dawley rats weremaintained for 15 days under CH (10% O2) or CHReox (10% O2 + 1 h day
1 exposure to air). Normoxic
(N, 21% O2) rats were the control. The animals were randomly assigned to one of the three following protocols: (1) protocol A: hearts (n = 7 per
group) were subjected to 30-min occlusion of the left anterior descending (LAD) coronary artery followed by 3-h reperfusion, with measurement
of the injury by tetrazolium staining; (2) protocol B: the end-diastolic pressure (EDP) and left ventricular developed pressure  heart rate
(LVDP  HR)weremeasured in Langendorff-perfused isolated hearts (n = 5 per group) during 30-min global ischaemia and 45-min reperfusion; and
(3) protocol C: hearts (n = 5 per group) were frozen for the determination of levels of endothelial nitric oxide synthase (eNOS) by Western
blotting. Results: CHReox hearts displayed greater phosphorylation of the eNOS and enhanced plasma level of nitrates and nitrites in comparison
to CH hearts (P < 0.0001, Bonferroni’s post-test). The infarct size was greater in CH than in N hearts (P < 0.0001, Bonferroni’s post-test) while it
was reduced in CHReox in comparison to CH and N hearts (P < 0.0001). At the end of reperfusion, EDP was higher in CH than CHReox and N hearts
(P = 0.01, Bonferroni’s post-test) while LVDP  HR was higher in CHReox and N than in CH hearts (P = 0.03, Bonferroni’s post-test). Conclusions:
Exposure to CH results in impairment of myocardial tolerance to ischaemia—reperfusion, greater injury and reduced recovery of performance, in
agreement with clinical evidence. Infarct size, diastolic contracture and myocardial performance have been reduced, respectively, by 63%, 64%
and 151% with daily reoxygenation compared with chronic hypoxia by accelerating intrinsic adaptive changes.
# 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Children with congenital cyanotic heart defects represent
one of the largest patient populations affected by the
deleterious consequences of chronic hypoxia (CH). The
results of surgical repair of cyanotic heart defects are
complicated by myocardial and multi-organ damage as a
consequence of acute reoxygenation at the moment of
institution of cardiopulmonary bypass with elevated oxygen
content, followed bymyocardial ischaemia required to arrest§ This study has been supported by Fondation Andreas P. Naef de la Chirurgie
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doi:10.1016/j.ejcts.2009.10.030the heart for the intra-cardiac repair with the subsequent
reperfusion [1]. The sequence of events is therefore hypoxia/
reoxygenation, followed by ischaemia—reperfusion.
In contrast to the evidence provided by the clinical
observations in congenital heart surgery, some studies have
shown that, in other situations, hypoxia confers a certain
degree of protection against ischaemia—reperfusion
damage. One example comes from populations living at
altitude, who are less prone to develop cardiovascular
diseases, despite lack of a causal relationship between
chronic hypoxia and myocardial protection [2,3]. Further-
more, cardiac protection by hypoxia was frequently reported
in experimental studies on animals investigating the
manifestations of ischaemia—reperfusion injury, such as
myocardial infarct size, [4] post-ischaemic contractile
dysfunction [5,6] and occurrence of arrhythmias [4,7].urgery. Published by Elsevier B.V. All rights reserved.
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exposed to ‘so-called’ chronic hypoxia (CH) in hypoxic
chambers intermittently opened to allow procedures such as
feeding, weighing and cleaning. The intermittent openings of
the chambers were associated with unavoidable and
repeated exposures to room air and therefore with episodes
of reoxygenation. We have proved [8] that hearts exposed to
CH display impaired tolerance to reoxygenation as compared
with normoxic hearts (control group) and also to hearts
exposed to intermittent reoxygenation (daily exposure to
room air) during CH [8], a protocol referred by us as CHReox.
CHReox and CH were found to cause different effects on the
regulation of sarcKþATP and mitoK
þ
ATP channels [9], mitogen-
activated protein kinases (MAPKs) [1], hypoxia-inducible
factor-1a [10], apoptosis [10] and nitric oxide (NO) [8], but
not on myocardial morphology [11]. Our most important
conclusions were that all the previously reported investiga-
tions using ‘so-called’ CH were, in reality, exposing the
animals to chronic hypoxia with daily reoxygenation
(CHReox). Therefore, the observation that ‘hypoxia confers
protection against the ischaemia—reperfusion damage’ was
only due to the fact that it was not CH but CHReox that was
responsible for the positive effects of myocardial protection.
Therefore, the negative effects of CH on the myocardial
function have never been thoroughly investigated, and
therefore, they cannot be denied on the base of the reported
literature.
So far it has not been determined whether CH and/or
CHReox may induce any degree of cardiac protection to
prevent or reduce the negative effects of the ischaemia—
reperfusion damage.
To answer the above question, this study has been
designed to:
(1) Determine the cardiac protection provided by CH and
CHReox in an animal model as close as possible to the
clinical practice, where hearts of cyanotic children
undergo reoxygenation, followed by myocardial ischae-
mia and reperfusion in chronological sequence; and
(2) Separate the intrinsic effects on the myocardium of CH
and CHReox from those related to the circulatory and
nervous factors.
2. Materials and methods
2.1. Animals
Fifty-one male Sprague-Dawley rats, weighing 248  1 g
at entry into the study, were divided into three groups (n = 17
per group): control group with normoxia (N, breathing room
air at 21% O2 saturation for 15 days), chronic hypoxia (CH,
breathing a normobaric gas at 10% O2 saturation and 90% N2
for 15 days) and chronic hypoxia with daily reoxygenation
(CHReox, as in CH, but daily exposed to room air 1 h day1 for
15 days). All animals had free access to water and a
laboratory diet until 24 h before sacrifice. To achieve true CH
without any exposure to room air and therefore to avoid any
unwanted reoxygenation, a hypoxic compensation chamber
kept at 10% O2 saturation was used to perform daily
operations as cleaning and weighing the animals, as
previously described [12].After the 15 days of observation, all N animals were
anaesthetised (10 mg Na-thiopental 100 g1 and 1500 IU
heparin i.p.) in room air, while all CH and CHReox animals
were anaesthetised in the hypoxic compensation chamber,
and therefore maintained in hypoxic environment even
during the induction of anaesthesia. CHReox animals were
anaesthetised 24 h after the 15th daily exposure to room air,
therefore not immediately after exposure to reoxygenation.
All hearts were randomly assigned to one of three following
experimental protocols:
(1) Protocol A: Hearts were subjected to coronary occlusion
and reperfusion;
(2) Protocol B: Hearts were isolated and perfused in a
Langendorff system with Krebs—Henseleit buffer;
(3) Protocol C: Hearts were frozen for the biochemical
analyses.
The investigation conformed to the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised 1996)
and with Swiss law and local ethical committee guidelines for
animal research.
2.1.1. Blood
Immediately after heart harvesting, a blood sample was
withdrawn into two heparinised tubes as previously reported
[8,9].
2.1.2. Protocol A: Coronary occlusion and reperfusion in
vivo
The 21 anaesthetised animals (n = 7 for each group) were
placed over a heating platform at 37 8C and connected to a
mechanical ventilator after tracheotomy (tidal volume
2.5 ml at 50 strokes min1) using a Harvard Apparatus with
either room air or hypoxic atmosphere, respectively, for
normoxic and hypoxic groups CH and CHReox (no inhalant
anaesthetics). After left thoracotomy, a silk suture (6/0) was
passed around the proximal segment of the left coronary
artery, and a polyethylene catheter was used to form a snare.
All animals were allowed 10 min to reach steady state before
beginning regional ischaemia—reperfusion. After stabilisa-
tion, LAD coronary artery was snared and myocardial
ischaemia was maintained for 30 min by placing a haemo-
static clamp on the occluded snare. After 30 min, the heart
was reperfused for 3 h by releasing the snare; then the aorta
was mounted on a cannula and perfused with 15—20 ml saline
at room temperature to wash out the blood. The LAD
coronary artery was re-occluded and saturated Evans blue
(2 ml) injected to mark the ischaemic zone as tissue area
without the blue dye. The heart was frozen in liquid nitrogen
and stored at 20 8C until analysis. To investigate the infarct
and risk areas, the frozen heart was cut into five to six 1-mm-
thick transverse slices from apex to base. The areas at risk
were identified as the areas demarcated with Evans blue dye,
whereas the non-infarcted and infarcted areas were
demarcated after incubation with 1% triphenyltetrazolium
chloride (TTC, Sigma) phosphate buffer (pH 7.4) at 37 8C for
20 min and fixed in 10% formalin for 4 days to enhance
contrast of the Evans blue and TTC staining. With the use of
NIH Image software (National Institutes of Health, Bethesda,
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Table 1
Homeostasis and blood values in animals exposed for 15 days to normoxia (N),
chronic hypoxia (CH) and chronic hypoxia with daily reoxygenation (CHReox).
Data are mean  SD. ANOVA P < 0.05 for all variables.
n N CH CHReox
12 12 12
Initial body weight (g) 248  3 247  8 250  5
Final body weight (g) 340  8 252  10 * 269  5*,#
Heart weight (mg) 1203  23 1383  58 * 1326  29*,#
Heart weight/body
weight (mg g1)
3.54  0.07 5.57  0.22 * 5.21  0.09*,#
Haematocrit (%) 51  2 66  2 * 68  1 *
Haemoglobin (g l1) 158  4 200  7 * 218  3 *
Red blood cell count
(RBC/ml/1000)
8.6  0.4 10.4  0.4 * 9.8  0.2 *
* P < 0.05 versus N.
# P < 0.05 versus CH (Bonferroni’s post-test).Maryland, USA), the different areas were quantified. The risk
areas have been defined as = (non-infarcted + infarcted
areas/total ventricular area)  100. Infarct size has been
defined as = (infarcted area/risk area)  100.
2.1.3. Protocol B: Langendorff-perfused isolated heart in
ex vivo model
The 15 anaesthetised animals (n = 5 for each group) were
dissected in the compensation chamber at 10% O2 saturation;
then the heart was quickly removed and immersed in a
beaker containing de-aerated isotonic saline at 25 8C; the
beaker was taken out of the chamber, the aorta immediately
cannulated and connected to the perfusion system and the
heart perfused at 37 8C with the hypoxic medium containing
6% CO2 at pH 7.39  0.01 as previously reported [8,9]. Hearts
were stabilised for 30 min at 10% O2 saturation. During this
period, the balloon volume was set to an end-diastolic
pressure (EDP) of 10 mmHg and kept constant afterwards. At
the end of the hypoxic stabilisation, hearts were subjected to
30-min reoxygenation at 100% O2 saturation, followed by 30-
min global ischaemia at 37 8C and 45-min reperfusion. The
performance was continuously monitored, but data were
reported every 5 min for clarity. Wemeasured EDP, heart rate
(HR), peak systolic pressure (PSP), left-ventricle developed
pressure (LVDP or PSP—EDP), coronary perfusion pressure,
maximal rate of heart contraction (+dP/dtmax) and relaxation
(dP/dtmin) and LVDP  HR. At the end of reperfusion, both
the atria were resected, the ventricles were weighed and
stored at 20 8C until analysis. To measure the infarct size,
the ventricles were cut into 1 mm transverse sections from
apex to base (five to sixslices per heart). Once thawed, the
slices were incubated at 37 8C with 1% triphenyltetrazolium
chloride in phosphate buffer (pH 7.4) for 20 min and fixed in
10% formalin for 4 days to enhance the contrast between
stained (viable) and unstained (damaged) areas. The infarct
size was determined from imaging the slices (NIH Image
AutoExtractor 1.51) and expressed as percentage of ven-
tricular size.
2.1.4. Protocol C: eNOS and phosphorylated-eNOS
The frozen tissue of 15 hearts (n = 5 for each group) was
homogenised in Ripa buffer solution containing protease
inhibitor cocktail (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Cell lysates were centrifuged (15 min at 13 000 rpm,
4 8C). Supernatants were transferred to pre-cooled micro-
centrifuge tubes, frozen in liquid nitrogen and stored at
80 8C. Total protein was measured by the BSA protein assay
kit (Thermo Scientific). Equal concentrations of protein from
each sample (80 mg) weremeasured byWestern blotting using
primary antibodies for eNOS (N-20: sc-653) and phosphory-
lated eNOS (Ser1177) (Santa Cruz Biotechnology) on an 8%
denaturating gel, followed by incubation with horseradish
peroxidase (HRP)-conjugated secondary antibody B; intensity
was quantified by NIH AutoExtractor-1.51 software. The same
extract from a normoxic heart was loaded on all blots for
quantitative comparisons between blots.
2.2. Statistics
Data are expressed as mean  SD. Significance level was
P = 0.05 (two-tailed). To detect differences among thegroups, we performed one- or two-way ANOVA. If this test
resulted significant, the differences between selected pairs
of data were tested using the Bonferroni’s procedure
(StatView, Abacus Concepts, Berkeley, CA, USA).
3. Results
3.1. Body weight and blood values
In agreement with previous studies [9] both types of
chronic hypoxia (CH and CHReox) led to marked polycythae-
mia, irrespectively of daily reoxygenation (Table 1). The
normal gain in body weight observed in the control normoxic
group (N) over the 15-day observation period was signifi-
cantly decreased by CH; this negative effect was partially
reduced by 1 h of daily reoxygenation in CHReox. The heart/
body weight ratio was higher for CH than for CHReox rats.
3.2. Daily reoxygenation decreases infarct size after LAD
occlusion in vivo
The extension of the area at risk was the same in all
groups, indicating that the consequences of the ligature of
the LAD coronary artery presented the same degree of
severity in all groups (Fig. 1).
The infarct size was greater in CH than N hearts
(68.5  2.4% vs 46.5  4.4%, P < 0.0001). Daily reoxygena-
tion during hypoxia reduced the infarct size to 23.8  2.8% of
the area at risk (P < 0.0001 vs CH).
3.3. Daily reoxygenation improves the post-ischaemic
recovery of myocardial performance in ex vivo model
Wemonitoredmyocardial function in Langendorff-perfused
isolated hearts exposed to 30-min global ischaemia and 45-min
reperfusion (Fig. 2). During hypoxic baseline perfusion, EDP
remained unchanged in all groups. The reoxygenation
decreased EDP in all hearts, but more so in CHReox hearts.
During the subsequent global no-flow ischaemia, EDP
increased, reflecting increasingdiastolic stiffness,more severe
for N than hypoxic hearts (CH and CHReox). After 45 min
reperfusion, final EDP was higher in CH (46.9  4.1 mmHg,
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Fig. 1. Daily reoxygenation reduces injury after LAD coronary artery occlusion
and reperfusion in vivo. The top panel shows representative sections of hearts
taken at the end of the 30-min LAD occlusion followed by 3-h reperfusion in the
three groups. White and red areas mark the infarct and vital. Averaged area at
risk (middle panel) and infarct size (bottom panel) are shown as mean  SD
(n = 5 per group). The one-way ANOVA P value is therein reported. *, versus
normoxia; #, versus chronic hypoxia (Bonferroni’s post-test).
Fig. 2. Daily reoxygenation improves myocardial performance after ischae-
mia—reperfusion. Time course of the end-diastolic pressure (top panel) and
the double product developed pressure  heart rate (bottom panel) during the
baseline, reoxygenation, ischaemia and reperfusion sequence (mean  SD;
n = 5 per group). The two-way ANOVA P value is reported. *, P = 0.02 versus
normoxia; #, P = 0.03 versus chronic hypoxia (Bonferroni’s post-test).n = 5) than in CHReox and N (33.5  3.2 and 35.1 3.0 mmHg,
n = 5 and 5, respectively) hearts.
The changes inmyocardial contractility were evaluated by
measuring the product LVDP  HR. This parameter was the
same in all groups until the end of global ischaemia. After
reperfusion, LVDP  HR was higher in CHReox and N
(12.8  1.6 and 14.1  2.8 mmHg  103 min1, respectively)Fig. 3. Daily reoxygenation improves systolic function after ischaemia—reper-
fusion. Heart rate (HR), left ventricular developed pressure (LVDP), maximal
rates of heart contraction (+dP/dtmax) and relaxation (dP/dtmin) and cor-
onary pressure at the end of reperfusion (mean  SD; n = 5 per group). The
two-way ANOVA P value is reported. The one-way ANOVA P value is therein
reported. *, versus normoxia; #, versus chronic hypoxia (Bonferroni’s post-
test).
G. Milano et al. / European Journal of Cardio-thoracic Surgery 37 (2010) 942—949946
Fig. 4. Daily reoxygenation reduces injury after ischaemia-reperfusion ex-
vivo. The top panel shows representative sections of hearts taken for the three
groups at the end of the Langendorff experiments, with white areas marking
the infarct. The bottom panel shows the infarct size averaged for all hearts and
expressed as percentage of ventricular size (mean  SD; n = 5 per group). The
one-way ANOVA P value is therein reported. *, versus normoxia; #, versus
chronic hypoxia (Bonferroni’s post-test).
Fig. 5. Daily aeration increases plasma nitrates + nitrites (NOx, top panel) and
phosphorylated eNOS (bottom panel). The intensity of the blots from 5 hearts
per groupwasmeasured by densitometry, averaged and reported in the bottom
panel as phosphorylated/total ratio (mean  SD; n = 5 per group). The one-
way ANOVA P value is therein reported. *, versus normoxia; #, versus chronic
hypoxia (Bonferroni’s post-test).than in CH hearts (8.5  2.8 mmHg  103 min1). We have
observed the same trend for LVDP, + dP/dtmax and dP/dtmin
(Fig. 3) at the end of reperfusion. No significant differences
were observed for HR and perfusion pressure (Fig. 3).
To provide a further marker of injury, reperfused hearts
were harvested tomeasure the infarct size by a colourimetric
technique (Fig. 4). CH hearts displayed the greatest
extension of the infarct (40  3% vs 25  2% and 22  4% in
CHReox and N, respectively), especially in the epicardial
region, in agreement with previously reported observations
[13].
3.4. Daily reoxygenation improves NO signalling
Exposure to CH induced an increase in plasma nitrates + -
nitrites (NOx), a marker of NO production. This increase was
higher in CHReox than in CH rats (Fig. 5). The expression level
of eNOS was unaffected by both CH and CHReox, but eNOS
phosphorylation was halved in CH with respect to N. By
contrast, eNOS phosphorylation recovered almost fully in
CHReox hearts.
4. Discussion
The results of this experimental study showed that daily
reoxyenation during CH markedly limited ischaemia—reper-
fusion injury both in the in vivo LAD coronary artery occlusion
and in the ex vivo Langendorff-perfused heart models. Thereduction of myocardial injury was also demonstrated by the
improved recovery of the ventricular performance.
4.1. The chronic hypoxia model
We previously reported that 1 h of daily reoxygenation
during CH improves tolerance to reoxygenation regardless of
blood oxygen content, haemoglobin concentration and
ventricular hypertrophy [8,11]. In our original model of
chronic hypoxia, animals are cared for and sacrificed under
truly hypoxic conditions, constantly preventing any exposure
to air.
The CH protocol thus closely mimics the physiological
(high altitude) and pathophysiologic (cyanotic congenital
heart defects, pulmonary diseases and severe anaemia)
settings where tissue oxygenation remains substantially
reduced to critical levels.
Virtually all studies employing standard hypoxic chambers
report that the so-called ‘chronic hypoxia’ is characterised
by protective effects [4—7]. By contrast, the studies where a
real CH was induced by surgical techniques [14—17] or in
chambers preventing aeration [8,9,11,17], demonstrated
that hypoxia is a risk factor. These apparently contradictory
findings can be explained by the observations of the present
experimental study. If ‘chronic hypoxia’ in standard hypoxic
chambers is similar to our CHReox protocol considering that
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surprising that the so-called ‘chronic hypoxia’ was protec-
tive, as opposed to deleterious effects of true CH, in
agreement with the clinical observations.
Thus, it is not hypoxia that conferred protection, but daily
reoxygenation associated with the use of standard hypoxic
chambers. Remarkably, the signal transduction pathways
originating from antioxidants, enzymes and stress proteins
were found to be critical in generating adverse effects during
CH, as opposed to protective effects in intermittent hypoxia,
a variant of CHReox [18]. While that study was the first to
propose that CH impairs recovery after ischaemia—reperfu-
sion, the present report is the first validation of the above
hypothesis.
The main factors accounting for the differences between
CH and CHReox may be related to the ox-redox balance and
increased oxidative stress associated with reoxygenation [8].
This hypothesis is confirmed by the augmented blood lipid
hydroperoxides and malondialdehyde during intermittent
hypoxic training, as opposed to attenuation of that increase
in regular hypoxic training [19]. However, the previous
investigations failed to prove that daily exposure to oxidative
stress might induce myocardial protection.
4.2. Myocardial ischaemia/reperfusion injury and
function
In this study, we made the original observation that the
size of myocardial infarction following LAD occlusion was
significantly reduced by daily reoxyenation during exposure
to chronic hypoxia than in normoxic hearts (Fig. 1).
A possible explanation could be the increase of the
plasmatic NOx in vivo following repeated episodes of
reoxyenation during chronic hypoxia (Fig. 5). Plasma NOx
represents an index of NO production and therefore an
increase in NO production in CHReox. NO is involved in the
ischaemic preconditioning, where short antecedent ischae-
mic periods render tissue more resistant to subsequent
prolonged and potentially lethal ischaemic insults [20]. NO
has been shown to have an important role in ischaemic
preconditioning and cardioprotection [21].
The in vivo LAD occlusion model is a close reproduction of
the clinical situation encountered when a coronary artery
lesion is complicating either the natural history or the
surgical repair of a congenital heart disease. However, the
identification of the specific role of intrinsic changes in
myocardial tissue metabolism may be difficult with that
model, because of the presence of potentially confounding
factors correlated with the circulation. In the ex vivo
Langendorff model, such factors are excluded because
enervated hearts are separated from the circulation and
perfused with the same medium throughout, thereby
emphasising the role of intrinsic factors. The employed ex
vivo protocol (hypoxic baseline, reoxygenation, global
ischaemia and reperfusion) enables separating the effects
due to oxygenation of CH hearts from those due to
ischaemia—reperfusion, thereby facilitating the comparison
among the three groups of hearts. That protocol also mimics
the sequence of events to whom hearts of children with
cyanotic congenital heart defects are subjected at the
moment they undergo cardiopulmonary bypass and myo-cardial ischaemia—reperfusion to perform intra-cardiac
repair.
With regard to the duration of reperfusion, in this study, in
the ex vivo model with chronic hypoxia, the infarct size was
reduced by daily reoxygenation after 45 min of reperfusion
(Fig. 4). The duration of 45 min has been based on a recent
study where the infarct size has been analysed after only
30 min of reperfusion, sufficient to induce myocardial
damage [22].
The advantages of employing isolated heart model include
accurate grading of hypoxia, no interference from blood—O2
affinity changes, red cell spacing within capillaries, haemo-
globin—O2 unloading kinetics, lymphocyte-mediated inflam-
matory processes, hormones, coagulation factors and
capillary clogging phenomena. Most of these phenomena
are altered by hypoxia, which also increases blood viscosity
due to raised haematocrit and induces haematocrit hetero-
geneity in the various districts of the myocardium.
However, although the crystalloid-perfused heart repre-
sents a reasonable approach to the in vivo situation, we agree
that doubts remain regarding the validity of the model in
situations far from the normal physiology.
Despite the above points, the outcomes of the ex vivo and
the in vivo models are remarkably similar, supporting the use
of these models for the aims of this study. Moreover, our
observation confirmed that cardiac protection was not
enhanced by the presence of factors residing in the
circulation, but the myocardial tissue itself underwent
intrinsic changes enabling greater protection against ischae-
mia—reperfusion.
A previous report [23] demonstrated that the negative
effects of ischaemia-reperfusion can be reduced in children
undergoing cardiac surgery, even if in this application on
human subjects, the target of ischaemia—reperfusion was
remote tissue and not myocardium. These researchers made
an important contribution not only to prove the existence of
the ischaemia-reperfusion damage with its clinical conse-
quences, but also to provide the clinical confirmation of the
validity of several experimental studies.
4.3. Limits of the study
Differing from altitude dwellers with healthy hearts,
children with cyanotic congenital heart defects usually
present with ventricular hypertrophy, pressure and/or
volume overload, heart failure or the combination of the
above. Furthermore, the underlying changes of their
myocardial structure and function are often aggravated by
chronic hypoxia. By contrast, our animals present with
structurally normal hearts, and they became hypoxic at 5
weeks of age, and only at this time the deleterious effects of
chronic hypoxia affect heart, lungs and other organs and
systems. To limit this potentially confounding variable, a
model of hypoxia immediately after birth was developed
[24]. In this model hypoxic kits are regularly returned to their
mother in a normoxic environment for 20 min once or twice a
day, thus exposing kits to reoxygenation as in CHReox in the
present study.
In this study, as in our previous investigations [9], we
demonstrated that reoxygenation alters the pattern created
by true chronic hypoxia, for example, the real situation of
G. Milano et al. / European Journal of Cardio-thoracic Surgery 37 (2010) 942—949948children with cyanotic congenital heart defects. Of course,
caution should be used when transferring information
obtained in experimental studies to the clinical scenario of
cyanotic children hypoxic since birth who undergo surgery for
the repair of their congenital heart defect. Nevertheless, in
the clinical practice, there are situations where, after a
period of relatively normal O2 saturation, a progressive
cyanosis develops at few weeks of age because of progressive
reduction of the effective pulmonary blood flow, as in
patients with tetralogy of Fallot, transposition of the great
arteries with ventricular septal defect and pulmonary
stenosis, functionally single ventricles with pulmonary
stenosis, double discordance (or congenitally corrected
transposition of the great arteries) with ventricular septal
defect and pulmonary stenosis, double outlet right ventricle
with ventricular septal defect and pulmonary stenosis. In all
these patients, the degree of dynamic obstruction to the
pulmonary blood flow can substantially increase during the
first few weeks after birth, leading to a progressive increase
of cyanosis. All these situations are not much different from
our animals made cyanotic 5 weeks after birth.
The myocardial ischaemia obtained with LAD occlusion is
limited to a portion of the left ventricle to mimic a coronary
artery lesion complicating the surgical repair of a congenital
heart defect. These cyanotic patients are first exposed to
reoxygenation at the beginning of cardiopulmonary bypass,
and then to myocardial ischaemia because of the aortic cross
clamping required to arrest the heart for the intra-cardiac
repair, and finally, to myocardial reperfusion after the aortic
cross clamp is removed. This scenario is closely mimicked in
the present protocol.
Finally, we decided not to pace these hearts, as in previous
studies [25], to consider the spontaneous heart rate response
as one of the variables resulting from the induced myocardial
injury.
5. Conclusions
Exposure to chronic hypoxia for 15 days results in impaired
myocardial tolerance to ischaemia/reperfusion, greater
injury and reduced recovery of performance, in agreement
with clinical evidence. Daily reoxygenationmarkedly reduces
the hypoxia-induced derangements by accelerating intrinsic
adaptive changes in the myocardium. Although a causal
relationship with NO metabolism still needs to be studied,
these findings correlate with enhanced NO signalling via up-
regulation of the endothelial isoform of NO synthase.
The observations of this study could possibly improve the
results of surgical repair in infants with cyanotic heart
defects. The results in paediatric cardiac surgery are still
associated with the risk of myocardial and/or multi-organ
damage. In our opinion, these are the consequence of acute
reoxygenation at the moment of institution of cardiopul-
monary bypass with elevated oxygen content, followed by
myocardial ischaemia required to arrest the heart for the
intra-cardiac repair with the subsequent reperfusion [1]. As
in our experimental studies, in the daily clinical practice, the
sequence of events remains hypoxia/reoxygenation, fol-
lowed by ischaemia—reperfusion. The reported findings may
be useful to design and evaluate alternative approaches ofsurgical plan, conduction of cardio-pulmonary bypass and
myocardial protection, aimed at protecting immature hearts
requiring a period of ischaemia—reperfusion for the surgical
repair of their congenital heart defect.
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